Intranasal administration
A nosepiece for delivering substance to a nasal cavity of a subject, the nosepiece comprising a body part which comprises a base portion which defines a flow passage therethrough, and a projection at a distal end of the base portion which at least in part provides a tip of the nosepiece and confers a rigidity in the sagittal direction, which enables the tip to open fleshy tissue at an upper region of the nasal valve and thereby expand an open area of the nasal valve, and a flexibility in a lateral direction, orthogonal to the sagittal plane, which facilitates insertion of the tip into the nasal valve.
1. A method of delivering a substance to a nasal cavity of a subject, comprising:
causing a nosepiece of a delivery device to be fitted in a nostril of the subject, the device further including an inner body part having a base portion and a projection in the form of a blade, an outer body part disposed about at least a portion of the inner body part and defining a distalmost tip of the nosepiece, the inner body part defining a flow path through the nosepiece, the base portion having a distal end defining a substantially annular surface surrounding the flow path, and the projection having a length in a first, sagittal direction in the sagittal plane greater than a length in a second, lateral direction, orthogonal to the sagittal plane and being cantilevered from the distal end of the base portion and extending toward and configured to support the distalmost tip of the outer body part; and
causing the distalmost tip supported by the blade to engage fleshy tissue at an upper region of the nasal valve of the subject to thereby expand and increase an opening of the nasal valve.
2. The method of claim 1 , wherein the inner body part is formed of a first material and the outer body part is formed of a second, different material, the first material being relatively more rigid than the second material.
3. The method of claim 1 , wherein the projection extends axially in a direction substantially parallel to a longitudinal axis of the nosepiece.
4. The method of claim 1 , wherein the substance is a liquid.
5. The method of claim 1 , wherein the substance is a peptide.
6. The method of claim 1 , wherein the substance is Orexin-A.
7. The method of claim 1 , wherein the substance is insulin.
8. The method of claim 1 , wherein the substance is oxytocin.
9. The method of claim 1 , wherein the substance is a non-peptide agonist of oxytocin.
10. The method of claim 1 , wherein the substance is a non-peptide antagonist of oxytocin.
11. The method of claim 8 , further including causing less than 24 IU of the oxytocin to be delivered to the upper region of the nasal valve of the subject.
12. The method of claim 9 , further including causing less than 24 IU of the non-peptide agonist of oxytocin to be delivered to the upper region of the nasal valve of the subject.
13. The method of claim 10 , further including causing less than 24 IU of the non-peptide antagonist of oxytocin to be delivered to the upper region of the nasal valve of the subject.
14. The method of claim 1 , further including causing modulation of conditions relating to social cognition and/or behavior in the subject.
15. The method of claim 1 , further including causing treatment of narcolepsy.
16. The method of claim 1 , further including causing treatment of diabetes.
17. The method of claim 1 , further including causing the subject to exhale through a mouthpiece of the delivery device to cause a flow of exhalation breath into the mouthpiece, through the delivery device, out of the nosepiece, and into the nasal cavity of the subject.
18. The method of claim 1 , further including causing a manually-actuatable delivery unit to deliver the substance through the nosepiece.